Literature DB >> 20812045

[Germ cell cancer--an update].

M Schrader1.   

Abstract

Recently a rise in the incidence of testicular germ cell cancer (TGCC) has been repeatedly reported in Germany (18% during the period 2000-2006). Future investigations are needed to examine causes for this increase in TGCT. The mortality rates in the western and eastern parts of Germany converge, but there is still a significantly higher mortality rate in the eastern part. Again future investigations are needed to examine causes for this phenomenon. In cases of testicular microlithiasis, testicular biopsies should be considered if further factors representing testicular dysgenesis syndrome are present, such as infertility, atrophic testes, and undescended testes. One course of adjuvant BEP reduces the risk of relapse by approximately 90% and may be a new option as the initial treatment for all CS1 NSGCT. Patients obtaining a CR (<1 cm) after first-line chemotherapy can be safely observed without PC-RPLND. Relapses are rare and potentially curable with further treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20812045     DOI: 10.1007/s00120-010-2375-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  8 in total

1.  Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?

Authors:  Yaron Ehrlich; Mary J Brames; Stephen D W Beck; Richard S Foster; Lawrence H Einhorn
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

2.  Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.

Authors:  R T D Oliver; M D Mason; G M Mead; H von der Maase; G J S Rustin; J K Joffe; R de Wit; N Aass; J D Graham; R Coleman; S J Kirk; S P Stenning
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

3.  A 5-year followup study of asymptomatic men with testicular microlithiasis.

Authors:  Brian J DeCastro; Andrew C Peterson; Raymond A Costabile
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

4.  Quality of surveillance for stage I testis cancer in the community.

Authors:  Hua-yin Yu; Rodger A Madison; Claude M Setodji; Christopher S Saigal
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

5.  Posttreatment surveillance after paraaortic radiotherapy for stage I seminoma: a systematic analysis.

Authors:  Johannes Classen; Rainer Souchon; Thomas Hehr; Michael Hartmann; Jörg T Hartmann; Michael Bamberg
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-14       Impact factor: 4.553

6.  Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy.

Authors:  R T D Oliver; J Ong; J Shamash; R Ravi; V Nagund; P Harper; M J Ostrowski; B Sizer; J Levay; A Robinson; D E Neal; M Williams
Journal:  Urology       Date:  2004-03       Impact factor: 2.649

7.  The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis.

Authors:  T Powles; D Robinson; J Shamash; H Moller; N Tranter; T Oliver
Journal:  Ann Oncol       Date:  2007-11-28       Impact factor: 32.976

8.  Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.

Authors:  Torgrim Tandstad; Olav Dahl; Gabriella Cohn-Cedermark; Eva Cavallin-Stahl; Ulrika Stierner; Arne Solberg; Carl Langberg; Roy M Bremnes; Anna Laurell; Hans Wijkstrøm; Olbjørn Klepp
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.